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Introduction {#sec006}
============

Potassium disturbances are common and have been associated with increased mortality in several populations, namely in those with diabetes \[[@pone.0236934.ref001]--[@pone.0236934.ref003]\], chronic kidney disease (CKD) \[[@pone.0236934.ref002]--[@pone.0236934.ref007]\], myocardial infarction (MI) \[[@pone.0236934.ref008], [@pone.0236934.ref009]\], hypertension \[[@pone.0236934.ref009], [@pone.0236934.ref010]\] and heart failure (HF) \[[@pone.0236934.ref002], [@pone.0236934.ref003], [@pone.0236934.ref006], [@pone.0236934.ref009], [@pone.0236934.ref011]--[@pone.0236934.ref014]\]. In these populations, potassium levels have been associated with outcomes in a U-shaped manner, where both hypo- and hyperkalemia portend worse prognosis.

Most studies in the ED have been performed in specific populations, including CKD \[[@pone.0236934.ref015]\], acute MI \[[@pone.0236934.ref008], [@pone.0236934.ref016]\] and HF \[[@pone.0236934.ref012]\] or subsequently admitted to critical care \[[@pone.0236934.ref017]\], or not centered on potassium levels \[[@pone.0236934.ref018], [@pone.0236934.ref019]\] or otherwise descriptive of severe hyperkalemia \[[@pone.0236934.ref020]--[@pone.0236934.ref023]\]. Among these, only one study was conducted prospectively \[[@pone.0236934.ref012]\]. Patients included in these previous studies thus represent a high-risk subset, and not the general population presenting at the ED except for one retrospective and monocentric study \[[@pone.0236934.ref021]\]. On the other hand, potassium disturbances and its clinical implications have been less described among people from the general population presenting at the emergency department (ED \[[@pone.0236934.ref005], [@pone.0236934.ref006], [@pone.0236934.ref008], [@pone.0236934.ref017], [@pone.0236934.ref018], [@pone.0236934.ref024], [@pone.0236934.ref025]\].

The present study aims to assess the prevalence of dyskalemia in the general population presenting at the ED without unstable medical conditions. Moreover, we aim to describe the factors and the prognostic implications of potassium disturbances.

Materials and methods {#sec007}
=====================

The present study is a post-hoc analysis of the Adverse Drug Events and Self-medication in Emergency Departments (ADES-ED) cohort \[[@pone.0236934.ref026]\], which aimed at determining the frequency and severity of adverse drug reactions (ADR) related to self-medication (ADR-SM) among patients attending the ED, and also to describe their main characteristics.

The ADES-ED study was a prospective, cross-sectional, observational study conducted over a period of 8 weeks (1 March to 20 April 2010), in the ED of 11 French academic hospitals. The centers were: CHU of Clermont-Ferrand, CHU of Caen, CHU of Toulouse, CHU of Nantes, CHU of Paris-Hôtel-Dieu Hospital, CHU of Rennes, CHU of Paris-Saint Antoine Hospital, CHU of Paris-Mondor Hospital, CHU of Grenoble, CHU of Paris-Cochin Hospital, and CHU of Angers.

Recruitment method in the ADES-ED cohort {#sec008}
----------------------------------------

The source population was all subjects 18 years of age and older who were likely to be admitted to a participating University Hospital emergency department during the study period.

The study population was identified by a pair of students (hospital medical students and fifth year hospital-university pharmacy students) trained in patient selection and data collection, with the help of the Nurse Organizer of the Reception Centre.

A high volume of visits in participating EDs precluded an uninterrupted prospective screening for inclusion throughout the study period. Therefore, we included patients presenting during different time-periods that were randomly selected (at each center level) by a central computer, thereby limiting selection bias associated with ED circadian cycles \[[@pone.0236934.ref026]\].

Criteria for inclusion:

All adult patients 18 years of age and older admitted to one of the 11 investigative centers during one of the collection periods.

Exclusion criteria: deliberate drug intoxication;patient refusal to participate in the study;patient's inability to give consent.

ADES-ED study design {#sec009}
--------------------

Patient demographics were collected from administrative data of each participating center over the same 8-week enrolment period. These data were compared with the overall study population to verify the representativeness of the studied ED population \[[@pone.0236934.ref026]\]. All adult patients presenting to the ED during one of the randomly assigned time slots were eligible for study participation.

All patients entering the study signed an informed consent form.

Self-medication and medical history were assessed by a standardized questionnaire. This questionnaire was developed and validated by Roulet et al. \[[@pone.0236934.ref027]\]. The questionnaire contained a set of 20 closed-ended questions exploring all indications and dimensions of self-medication, and data regarding medical history.

Post-hoc study {#sec010}
--------------

Only patients with available potassium measurements were included in the present study.

Hypokalemia was defined according to two independently explored thresholds (\<4 and \<3.5mmol/L) \[[@pone.0236934.ref010]\], while hyperkalemia was defined as a plasma potassium \>5mmol/L \[[@pone.0236934.ref028]\]. We chose to use two thresholds because most authors define a potassium level \<4mmol/L as hypokalemia \[[@pone.0236934.ref029]\], but potassium levels \<3.5mmol/L may have a stronger prognostic association^3^ and were considered by others \[[@pone.0236934.ref030]\]. A normal potassium range was considered when potassium levels were between 4 and 5mmol/L or 3.5 to 5mmol/L depending on the threshold considered. CKD was defined as eGFR \<60 ml/min/1.73 m^2^. The primary study endpoint was all-cause hospitalization or death.

The study protocol and patient informed consent procedures were approved by the Ethics Committee (St. Etienne CHU on February 10 2008, ref:N/A) and by the Committee on Information in Health Research (CCTIRS ref:08.369/CNIL ref:AT/YPA/SV/SN/GDP/EM/AR081393) according to French regulations in clinical research.

Statistical analysis {#sec011}
--------------------

Continuous variables are expressed as mean ± standard deviation (SD) if normally distributed or as median and interquartile range if the distribution was skewed. Categorical variables are expressed as frequencies and proportions (%). Association between patient characteristics and dyskalemia was assessed using multinomial logistic regression including all variables with a p value \< 0.1 in [Table 1](#pone.0236934.t001){ref-type="table"} followed by a stepwise backward procedure for retaining the variables selected at a p value \< 0.05. Associations with the in-ED combined outcome (hospitalization and/or death) were studied with logistic regression models, using potassium as independent variable and adjusting for age, gender, estimated glomerular filtration rate, hemoglobin and thiazide diuretics, found to be associated with potassium levels in the previous model. We adjusted on age, gender, estimated glomerular filtration rate, hemoglobin and Thiazide: patients with K\>5 were indeed older, had lower eGFR and lower hemoglobin ([Table 1](#pone.0236934.t001){ref-type="table"}), all of which being associated with higher risk for death.

10.1371/journal.pone.0236934.t001

###### Characteristics of the study population overall and by potassium level categories (mmol/L).

![](pone.0236934.t001){#pone.0236934.t001g}

                              Overall        By potassium category                              
  --------------------------- -------------- ----------------------- ------------- ------------ ---------
  Age (years)                 57.2 ± 22.3    53.2±22.0               59.5±22.1     72.3±16.1    \<0.001
  Female gender               634            342 (55.2%)             263 (47.9%)   29 (39.7%)   0.006
  SBP (mmHg)                  139.2 ± 25.4   138±25                  140±24        140±32       0.30
  DBP (mmHg)                  77.7 ± 15.3    78±15                   77±14         72±16        0.011
  Heart rate (bpm)            85.7 ± 19.4    85±18                   86±19         86±21        0.72
  Diabetes                    132 (10.6%)    7 (1.1%)                10 (1.8%)     2 (2.7%)     0.43
  Hypertension                436 (35.1%)    189 (30.5%)             202 (36.8%)   45 (61.6%)   \<0.001
  Heart failure               120 (9.7%)     8 (1.3%)                10 (1.8%)     2 (2.7%)     0.56
  Atrial fibrillation         90 (7.9%)      7 (1.1%)                9 (1.6%)      0 (0.0%)     0.45
  Alcoolism                   42 (3.7%)      45 (7.9%)               38 (7.5%)     7 (11.1%)    0.60
  eGFR (ml/min/1.73m^2^)      92.4 ± 56.6    90±28                   82±30         53±33        \<0.001
  eGFR \<60 ml/min/1.73m^2^   223 (18.0%)    53 (10.6%)              116 (18.1%)   42 (59.2%)   \<0.001
  Glucose (mmol/L)            6.4 ± 2.4      6.2±2.3                 6.5±2.5       6.6±2.3      0.18
  Na^+^ (mmol/L)              138.9 ± 4.2    139±3                   138±4         137±6        0.002
  K^+^ (mmol/L)               4.1 ± 0.6      3.7±0.2                 4.3±0.2       5.5±0.6      \<0.001
  Hemoglobin (g/dL)           13.3 ± 2.2     13±1                    13±2          11±2         \<0.001
  NSAIDs                      168(13.5%)     87 (14.0%)              75 (13.7%)    6 (8.2%)     0.39
  MRAs                        41 (3.3%)      12 (1.9%)               21 (3.8%)     8 (11.0%)    \<0.001
  ACEi/ARB                    312(25.1%)     122 (19.7%)             152 (27.7%)   38 (52.1%)   \<0.001
  Beta-blockers               217(17.5%)     83 (13.4%)              112 (20.4%)   22 (30.1%)   \<0.001
  Corticosteroids             76 (6.1%)      30 (4.8%)               36 (6.6%)     10 (13.7%)   0.010
  CCBs                        143(11.5%)     67 (10.8%)              59 (10.7%)    17 (23.3%)   0.005
  Insulin                     73 (5.9%)      28 (4.5%)               33 (6.0%)     12 (16.4%)   \<0.001
  Loop-diuretic               155 (12.5%)    58 (9.4%)               79 (14.4%)    18 (24.7%)   \<0.001
  Thiazide-diuretic           115 (9.3%)     62 (10.0%)              42 (7.7%)     11 (15.1%)   0.081
  K binders                   11 (0.9%)      3 (0.5%)                5 (0.9%)      3 (4.1%)     0.007
  K supplements               67 (5.4%)      32 (5.2%)               26 (4.7%)     9 (12.3%)    0.025
  Deaths at emergency         2 (0.2%)       0 (0.0%)                2 (0.4%)      0 (0.0%)     0.28
  Hospitalization in ward     629 (52.7%)    300 (49.8%)             288 (55.1%)   41 (59.4%)   0.11
  Hospital critical care      16 (1.3%)      5 (0.8%)                9 (1.7%)      2 (2.9%)     0.22

SBP, systolic blood pressure; DBP, diastolic blood pressure; RR, respiratory rate; ACEi/ARBs, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; NSAIDs, nonsteroidal anti-inflammatory drugs; eGFR, estimated glomerular filtration rate (CKD-EPI formula), MRAs, mineralocorticoid receptor antagonists; CCBs, Calcium channel blockers.

Continuous variables were categorized to attain log-linearity. Odds-ratios are presented with their 95% confidence intervals as OR (CI 95%).

All analyses were performed using R^®^ software.

Results and discussion {#sec012}
======================

Characteristics of the study population {#sec013}
---------------------------------------

Overall, 3017 patients were included in the main study, while 1242 patients with available potassium measurements were included in the present sub-study ([Fig 1](#pone.0236934.g001){ref-type="fig"}). The chief complaint was abdominal pain in approximately one-quarter of the patients, with the other most frequent complaints being cardiovascular diseases, trauma and weakness.

![Flowchart.](pone.0236934.g001){#pone.0236934.g001}

Patient characteristics are presented in [Table 1](#pone.0236934.t001){ref-type="table"}. The mean age was 57.2±22.3 years. Approximately one third of the study population presented with a history of hypertension, 11% had diabetes mellitus, and 10% had a history of HF. The mean estimated glomerular filtration rate (eGFR) was 92±57 ml/min/1.73m^2^ (n = 223, 18% had an eGFR \<60 ml/min/1.73 m^2^). A minority of patients had potassium levels above 5mmol/L (n = 73; 6%). Of note, very few patients had a potassium level above 5.5mmol/L (n = 20; 2%), or above 6mmol/L (n = 1; 0.1%). In contrast, hypokalemia below 4mmol/L was highly prevalent (n = 620; 50%), while fewer patients displayed hypokalemia below 3.5mmol/L (n = 101; 8%).

Potassium distribution is presented in [Fig 2](#pone.0236934.g002){ref-type="fig"}. Patients with hypokalemia were younger and more often female, whereas patients with hyperkalemia had a lower eGFR and hemoglobin (compared with patients with normokalemia).

![Potassium distribution.](pone.0236934.g002){#pone.0236934.g002}

Patients treated with angiotensin-converting enzyme (ACEi) and angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), calcium channel blockers (CCB), loop diuretics, potassium supplements and insulin had a higher hyperkalemia rate ([Table 1](#pone.0236934.t001){ref-type="table"}).

Factors associated with hypokalemia {#sec014}
-----------------------------------

In multivariate analyses, female gender (OR \[95%CI\] = 1.31 \[1.03--1.66\], p-value = 0.029), younger age (age \<45 years: OR \[95% CI\] = 1.69 \[1.20--2.37\], p-value = 0.002) and thiazide diuretic use (OR \[95% CI\] = 2.04 \[1.28--3.32\], p-value = 0.003) were associated with hypokalemia \<4mmol/L ([Table 2](#pone.0236934.t002){ref-type="table"}).

10.1371/journal.pone.0236934.t002

###### Multinomial logistic regression analysis targeting factors associated with dyskalemia.

![](pone.0236934.t002){#pone.0236934.t002g}

  Variable                    Hypokalemia         p-value   Normokalemia   Hyperkalemia        p-value
  --------------------------- ------------------- --------- -------------- ------------------- ---------
  Female gender               1.31 (1.03--1.66)   0.029     \-             0.54 (0.31--0.92)   0.024
  Age \<45 year               1.69 (1.20--2.37)   0.002     \-             \-                  \-
  eGFR \<60 ml/min/1.73m^2^   0.64 (0.44--0.93)   0.020     \-             3.56 (1.94--6.52)   \<0.001
  Thiazide diuretics          2.04 (1.28--3.32)   0.003     \-             \-                  \-
  Hb \<12 g/dL                \-                  \-        \-             2.62 (1.50--4.60)   0.001

eGFR, estimated glomerular filtration rate based on the CKD-EPI formula; Hb, hemoglobin.

All variables with a p-value \< 0.1 in [Table 1](#pone.0236934.t001){ref-type="table"} were introduced into the model. A backward selection process was conducted with a 500x sampling bootstrap method.

Variables were categorized to attain log-linearity.

Hypokalemia defined as K^+^ \<4.0mmol/L.

Normokalemia defined as K^+^ 4.0--5.0mmol/L.

Hyperkalemia defined as K^+^ \>5.0mmol/L.

In a further sensitivity analysis of hypokalemia \<3.5mmol/L (with 3.5-5mmol/L as a reference), only thiazide diuretics were found associated with hypokalemia (OR \[95% CI\] = 2.32 \[1.28--4.17\], p-value = 0.005) ([S1 Table](#pone.0236934.s001){ref-type="supplementary-material"}).

Factors associated with hyperkalemia {#sec015}
------------------------------------

Renal insufficiency (OR \[95% CI\] = 3.56 \[1.94--6.52\], p-value \<0.001) and hemoglobin \<12g/dl (OR \[95% CI\] = 2.62 \[1.50--4.60\], p-value = 0.001) were found associated with hyperkalemia, while female gender was negatively associated (OR \[95% CI\] = 0.54 \[0.31--0.92\], p-value = 0.0024) ([Table 2](#pone.0236934.t002){ref-type="table"}).

Hospitalization and death {#sec016}
-------------------------

Two patients died in the ED, 629 (52.7%) were hospitalized and 16 (1.3%) were admitted to an intensive care unit ([Table 3](#pone.0236934.t003){ref-type="table"}). [Fig 3](#pone.0236934.g003){ref-type="fig"} presents the relationship between potassium level in blood and the combined outcome of hospitalization or death, the latter of which was found to be U-shaped, with a nadir at approximately 4.2mmol/L. In multivariate analysis, potassium was not associated with the combined outcome ([Table 3](#pone.0236934.t003){ref-type="table"}).

![Relationship between potassium level in blood and combined outcome of hospitalization or death.\
\*Model adjusted for age, gender, estimated glomerular filtration rate, hemoglobin and thiazide diuretics.](pone.0236934.g003){#pone.0236934.g003}

10.1371/journal.pone.0236934.t003

###### Associations between K^+^ levels and the outcome of hospitalization or death.
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  K^+^ levels (mmol/L)                                          Crude OR (95% CI)   p-value   Adjusted OR (95% CI)[\*](#t003fn001){ref-type="table-fn"}   p-value
  ------------------------------------------------------------- ------------------- --------- ----------------------------------------------------------- ---------
  K^+^ \<4.0                                                    0.75 (0.59--0.95)   0.015     0.89 (0.69--1.15)                                           0.38
  K^+^ 4.0--5.0 (ref.)[\*\*](#t003fn002){ref-type="table-fn"}   \-                  \-        \-                                                          \-
  K^+^ \>5.0                                                    1.25 (0.75--2.07)   0.40      0.68 (0.39--1.17)                                           0.16

\*Model adjusted for age, gender, estimated glomerular filtration rate, hemoglobin and thiazide diuretics.

\*\*The reference group is normokalemia: 4.0--5.0mmol/L.

In a sensitivity analysis, hypokalemia\< 3.5mmol/L was associated with the combined outcome of hospitalization or death (OR \[95% CI\] = 1.47 \[1.00--2.15\], p-value = 0.048) ([Table 4](#pone.0236934.t004){ref-type="table"}).

10.1371/journal.pone.0236934.t004

###### Associations between K^+^ levels and the outcome of hospitalization or death.
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  K^+^ levels (mmol/L)                                          Crude OR (95% CI)   p-value   Adjusted OR (95% CI)[\*](#t004fn001){ref-type="table-fn"}   p-value
  ------------------------------------------------------------- ------------------- --------- ----------------------------------------------------------- ---------
  K^+^ \<3.5                                                    1.37 (0.96--1.96)   0.079     1.47 (1.00--2.15)                                           0.048
  K^+^ 3.5--5.0 (ref.)[\*\*](#t004fn002){ref-type="table-fn"}   \-                  \-        \-                                                          \-
  K^+^ \>5.0                                                    1.51 (0.92--2.47)   0.10      0.61 (0.35--1.08)                                           0.09

\*Model adjusted for age, gender, estimated glomerular filtration rate, hemoglobin and thiazide diuretics.

\*\*The reference group is normokalemia: 3.5--5.0mmol/L.

Our study reports the prevalence, associated factors and prognostic implications of dyskalemia assessed in patients presenting at the ED in the absence of unstable medical illness. Hypokalemia was present in almost 50% of these patients, particularly among those less than 45 years old, in women, and those taking thiazide diuretics. Importantly, hypokalemia below 3.5mmol/L was associated with poorer outcomes. Conversely, hyperkalemia was less frequent in this population and not associated with adverse prognosis.

Our population characteristics are comparable to other low-risk cohorts \[[@pone.0236934.ref031], [@pone.0236934.ref032]\]. Moreover, similarly to Krokager et al. \[[@pone.0236934.ref033]\], who reported short-term mortality risk of potassium levels in hypertensive patients from the nationwide Danish registry, or in the Lindner et al. ED retrospective monocentric study \[[@pone.0236934.ref021]\], women were globally more susceptible to hypokalemia. The hypokalemia rates found in the present study were higher than in other reports \[[@pone.0236934.ref020], [@pone.0236934.ref021], [@pone.0236934.ref034]--[@pone.0236934.ref036]\].

For external validity purposes, we compared our prevalence results with another ED French cohort---the PARADISE cohort \"Pathway of dyspneic patients in Emergency", consisting of including all patients over one year aged 18 years or older admitted to the ED of the Nancy University Hospital (France) for dyspnea., as previously reported by our group \[[@pone.0236934.ref037]\].

In this setting, encompassing various nosological conditions, among 1318 dyspneic patients with potassium measurements, hypokalemia below 4mmol/ L was present in 36.6% of the patients, which was similar to what we found herein. Hyperkalemia above 5mmol/L was present in 6.8% of the patients.

An increase in the in-hospital short-term morbidity-mortality was observed in patients with potassium levels \<3.5mmol/L, a finding also observed in another ED study \[[@pone.0236934.ref035]\] as well as in myocardial infarction patient cohorts \[[@pone.0236934.ref008]\] and in both hypertensive \[[@pone.0236934.ref033]\] and chronic HF \[[@pone.0236934.ref029]\] patients or in meta-analysis \[[@pone.0236934.ref009]\]. In specific population, as our results, Zhang et al. \[[@pone.0236934.ref007]\] demonstrated in meta-analysis that hypokalemia (\<3.5mEq/L) was significantly associated with higher mortality risk among patients with CKD and dominant among women. Zhang et al also found that serum K within 3.5--4.0mEq/L among CKD patients was associated with increased all-cause risk. Potassium is an important determinant of myocardial function, and low blood potassium levels may cause arrhythmias and sudden cardiac death by accelerating depolarization, increasing automaticity and lengthening the action potential \[[@pone.0236934.ref029], [@pone.0236934.ref038]--[@pone.0236934.ref042]\].

The use of thiazide diuretics was associated with hypokalemia in our study. Their use may increase urinary potassium loss \[[@pone.0236934.ref043], [@pone.0236934.ref044]\]; hence, an appropriate electrolyte (and creatinine) monitoring is warranted in patients taking thiazides. However, certain studies have shown that the monitoring of potassium levels is suboptimal under potassium-sparing diuretics \[[@pone.0236934.ref045]\], particularly in primary care patients \[[@pone.0236934.ref046]\]. Upstream of the ED, i.e. in the primary care setting, there is indeed widespread use of thiazide diuretics, notably as long-run prescriptions in hypertensive patients (53.4% in hypertensive patients in the Danish registry \[[@pone.0236934.ref033]\], where the administration of diuretics in the low normal potassium level was slightly higher than the administration of ACEIs/ARBs). Thiazide diuretics were also found associated with hypokalemia in the ED in the present study, while "diuretic therapy" was found associated with both hypokalemia and hyperkalemia by Lindner et al. in their retrospective analysis of a single-center database in Switzerland \[[@pone.0236934.ref021]\]. Thus, an adequate biological monitoring is also warranted in hypertensive patients who are at risk of hypokalemia.

Our study has several limitations. First, the initial reasons for measuring potassium were not recorded and assessed, although the chief complaint of our population was comparable to those of the ADES-ED population (trauma in about one-third of the patients, with the other most frequent complaints being abdominal pain, weakness and cardiovascular diseases) \[[@pone.0236934.ref026]\], except for trauma which was second. This fact can be easily explained since patients with no potassium measurements were excluded in our study and patients with non-surgical trauma had no blood test. Secondly, data collection on drug consumption did not include dietary supplements, which can also generate iatrogenic effects, especially on potassium levels. Thirdly, the present dataset does not allow ruling out a pseudo-hyperkalemia phenomenon \[[@pone.0236934.ref047]\], in addition we don't know which machines were used to test their potassium values and what are the hospitals cut-offs for potassium. However, hyperkalemia was very uncommon in the present series. Another important limitation was that mortality was only assessed in the ED, while a more long-term analysis (i.e. during hospital stay) may also be relevant. Lastly, our population only included people who have had a blood test with electrolytes. This fact selects patients who are probably sicker than those who did not have blood tests.

Notwithstanding, the strength of the present study lies in its multicenter and prospective recruitment approach while describing for the first time a population presenting at the ED without unstable medical illness.

Conclusions {#sec017}
===========

Hypokalemia was frequently found in the ED. It was associated with worse outcomes in a low-risk ED population. Thus, ED patients presenting with hypokalemia should be appropriately treated and monitored both in the ED and after discharge. Furthermore, more effective prevention strategies encompassing an adequate biological monitoring of hypertensive patients treated with thiazide diuretics should be implemented upstream.

Supporting information {#sec018}
======================

###### Multinomial logistic regression for the factors associated with dyskalemia.

eGFR, estimated glomerular filtration rate based on the CKD-EPI formula; Hb, hemoglobin. All variables with a p-value of less than 0.1 in [Table 1](#pone.0236934.t001){ref-type="table"} were introduced into the model. A backward selection process was conducted with 500x sampling bootstrap method. Variables were categorized to attain log-linearity. Hypokalemia defined as K^+^ \<3.5 mmol/L (N = 148). Normokalemia defined as K^+^ 3.5--5.0 mmol/L (N = 1021). Hyperkalemia defined as K^+^ \>5.0 mmol/L (N = 73).
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\'The National Medicine Academy approved the study design and provided funding. The French Society for Clinical Pharmacy (SFPC) approved the protocol, supported the enrolment and training of pharmacy students and provided funding. The French Association of Pharmaceutical Manufacturers for a responsible self-medication (AFIPA) approved the protocol and the conduct of the study. Sanofi Aventis approved the protocol and the conduct of the study. None of these funding sources intervened in the collection, management, analysis or interpretation of the data; nor in the preparation, review or approval of the manuscript.\'
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6\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The following information needs to be included in the manuscript:

1\. The inclusion criteria of the ADES-ED study. Without it, the study group is not clearly defined.

2\. In line 102, a standardized survey was used. How was the survey validated?

3\. Line 116 mentions the PARADISE cohort. A detailed description of the cohort is needed. Why was this group chosen?

4\. Lines 106-107: describe why there are two different measures for hypokalemia being used for the study.

5\. My previous comment also relates to the two tables (3 & 4) looking at outcomes between a potassium less than 4 and 3.5. It is not clear to me why you need two tables.

6\. In the discussion section, you need to address the fact that your population included only those who had blood drawn. This inherently selects for those who are likely sicker than those who did not have blood drawn.

Reviewer \#2: This study by Ferreira et al. investigated the prevalence of dyskalemia in ED of multiple medical centers/hospitals across the France. This was done in a prospective and cross-sectional manner. It is interestingly showed that hypokalemia occurs most often in ED patients while hyperkalemia is rare. Though hypokalemia sounds like "low-risk" but is associated worse outcomes in terms of hospitalization and death. While this is very interesting, there are a couple of issues to be addressed:

1\. First of all, according to Table 1, there is more frequent hospitalization (including in ward and critical care) of patients with hyperkalemia than of patients with hypokalemia or normokalemia. This agrees with more treatments with cardiovascular drugs such as ACEi, CCB, and diuretics, suggesting these patients had CVD more frequently (e.g., hypertension). Please explain this is contradicting with Table 4. In Table 4, the crude OR was 1.51 for the association between hyperkalemia and outcomes but adjusted OR showed an OR\<1.0 (0.61). Why is that and what does this mean?

2\. Why in Table 3 and Table 4, K+\>5.0 had different OR and p values for the outcome of hospitalization or death?

3\. The comparison between your study with the French cohort of 1318 patients should be removed from the abstract and the results part. It is appropriate to keep that in the discussion.

4\. What does MRAs stand for in Table 1? Please make sure you have spelled out all abbreviations in the text and notes for tables.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Answers to reviewers

Journal Requirements

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf>

Response:

Done

and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response:

Done

2\. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

Response:

Thank you. The questionnaire has been previously published.

A copyright nevertheless prevents us from publishing it in our article. but we have now added the citation and details about this questionnaire Lines 120-121 in the version with tracked changes and Lines 101-102 in the new version:

"This questionnaire was developed and validated by Roulet et al in 2008."

3\. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants.

Please ensure you have provided sufficient details to replicate the analyses such as:

a\) a description of how participants were recruited, and b) descriptions of where participants were recruited and the names of the 11 French academic hospitals.

Response:

Thank you for that remark. The ADES-ED Cohort population was recruited from the emergency departments of 11 French hospitals. The participating centers were: CHU of Clermont-Ferrand, CHU of Caen, CHU of Toulouse, CHU of Nantes, CHU of Paris-Hôtel-Dieu Hospital, CHU of Rennes, CHU of Paris-Saint Antoine Hospital, CHU of Paris-Mondor Hospital, CHU of Grenoble, CHU of Paris-Cochin Hospital, and CHU of Angers (lines 87-90 in the version with tracked changes and lines 72-75 in the new version).

All subjects 18 years of age and older who were likely to be admitted to a UHC emergency department during the study period, were recruited. The exclusion criteria were: deliberate drug intoxication; patient refusal to participate in the study; and patient\'s inability to give consent.

The study population was identified by a pair of students. We have added a section dedicated of recruitment method to the lines 91-96 in the version with tracked changes and lines77-86 in the new version:

"Recruitment method in ADES-ED cohort

The source population was all subjects 18 years of age and older who were likely to be admitted to a participating University Hospital emergency department during the study period.

The study population was identified by a pair of students (hospital medical students and fifth year hospital-university pharmacy students) trained in patient selection and data collection, with the help of the Nurse Organizer of the Reception Centre.

And lines 101-107 in the version with tracked changes and line 87-93 in the new version:

"Criteria for inclusion:

All adult patients 18 years of age and older admitted to one of the 11 investigative centers during one of the collection periods.

Exclusion criteria:

\- deliberate drug intoxication;

\- patient refusal to participate in the study;

\- patient\'s inability to give consent. "

4\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Response:

The dataset we used was a subset of the main ADES-ED study. Since there are ethical restrictions for data access per French Regulation (sensitive healthcare data), we got access to it via Mrs Trombert, acting as a deputy of the trial sponsor and of the ADES-ED trial steering committee. More broadly, requests for access require the agreement of the study investigators and the study sponsor studying the applicant\'s project. You can contact this committee by mail: Ms Béatrice Trombert-Paviot. (<Beatrice.TROMBERT-PAVIOT@chu-st-etienne.fr> ; CHU of Saint Etienne, France) or Pr Patrice Queneau (<pat-queneau@orange.fr>, Saint Etienne university, France).

5\. Thank you for stating the following in the Financial Disclosure section:

\'The National Medicine Academy approved the study design and provided funding. The French Society for Clinical Pharmacy (SFPC) approved the protocol, supported the enrolment and training of pharmacy students and provided funding. The French Association of Pharmaceutical Manufacturers for a responsible self-medication (AFIPA) approved the protocol and the conduct of the study. Sanofi Aventis approved the protocol and the conduct of the study. None of these funding sources intervened in the collection, management, analysis or interpretation of the data; nor in the preparation, review or approval of the manuscript.\'

We note that you received funding from commercial sources: AFIPA and Sanofi Aventis

Response:

Our apologies for the confusion; the above statement actually was related to the main study, for which the initial authors also stated that "All authors have declared no potential conflicts of interest regarding this study." In this post-hoc analysis, there is no funding, as clarified in the cover letter.

a\. Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations\<<http://www.plosone.org/static/competing.action>\> relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Response:

As explained above, there is no funding source for this post-hoc analysis. This is now clarified in the cover letter.

b\. Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Response:

Done.

6\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

Response:

Dr Rossignol ORCID number is <https://orcid.org/0000-0001-8009-3873>

Reviewers\' comments

Reviewer \#1

The following information needs to be included in the manuscript:

1\. The inclusion criteria of the ADES-ED study. Without it, the study group is not clearly defined.

Response:

Thanks; we proceeded accordingly and inserted the following text in order to clarify the criteria of the ADES-ED study lines 101-107 in the version with tracked changes and lines 87-93 in the new version:

"Criteria for inclusion:

All adult patients 18 years of age and older admitted to one of the 11 investigative centers during one of the collection periods.

Exclusion criteria:

\- deliberate drug intoxication;

\- patient refusal to participate in the study;

\- patient\'s inability to give consent. "

2\. In line 102, a standardized survey was used. How was the survey validated?

Response:

The questionnaire has been previously published (Roulet et al, reference 27), with a copyright preventing us from publishing it within the present paper.

This Questionnaire to document self-medication was developed between January and September 2008 by Roulet et al; during the same period, spontaneous report of self-medication use was collected ("reference period"). The questionnaire was tested and reﬁned between October and December 2008 ("test period"). Finally, the QSMB was routinely used between January and December 2009 ("routine period"). After verifying that the patients interviewed during the reference and routine periods were not signiﬁcantly different with regard to baseline characteristics, Roulet et al assessed the utility of questionnaire by comparing the self-medication rates measured during these two periods.

We have now quoted this paper lines 119-120 in the version with tracked changes and lines101-102 in the new version:

"This questionnaire was developed and validated by Roulet et al (27)."

3\. Line 116 mentions the PARADISE cohort. A detailed description of the cohort is needed. Why was this group chosen?

Response:

Thank you for this remark; we now more accurately describe the PARADISE cohort. This cohort \"Pathway of dyspneic patients in Emergency", consisting of including all patients over one year aged 18 years or older admitted to the ED of the Nancy University Hospital (France) for dyspnea. This cohort included a total of 1,589 patients, including 1318 with a potassium measurement.

This cohort was chosen for several reasons:

\- It is a French population of patients presenting in the emergency department.

\- Our team made up this cohort. So we had easy access to the data.

We have added the sentence to lines 247-250 in the version with tracked changes and lines 222-225 in the new version:

"For external validity purposes, we compared our prevalence results with another ED French cohort - the PARADISE cohort \"Pathway of dyspneic patients in Emergency", consisting of including all patients over one year aged 18 years or older admitted to the ED of the Nancy University Hospital (France) for dyspnea., as previously reported by our group (29)."

4\. Lines 106-107: describe why there are two different measures for hypokalemia being used for the study.

Response:

Thank you. These cut-offs were chosen to have a better insight on the shape of the associations, as most authors define a potassium level \<4mmol/L as hypokalemia (reference 29), but potassium levels \<3.5mmol/L may have a stronger prognostic association, and were selected by other groups e.g. recently by Cooper et al Eur J Heart Fail. 2020 (reference 30).

Therefore, we wanted to assess both.

We have added the sentence to lines 126-129 in the version with tracked changes and lines 109-112 in the new version:

"We chose to use two thresholds because most authors define a potassium level \<4mmol/L as hypokalemia \[29\], but potassium levels \<3.5mmol/L may have a stronger prognostic association and were considered by others \[30\]."

We now also state that, line 130 in the version with tracked changes and lines 112-113 in the new version that:

"normal potassium range was considered when potassium levels were between 4 and 5mmol/L or 3.5 to 5mmol/L depending on the threshold considered"

5\. My previous comment also relates to the two tables (3 & 4) looking at outcomes between a potassium less than 4 and 3.5. It is not clear to me why you need two tables.

Response:

We have made two tables since there are actually two different analyses. Indeed, the association of K+\<3.5 with outcomes is stronger, therefore, we would like to maintain it for the reader.

6\. In the discussion section, you need to address the fact that your population included only those who had blood drawn. This inherently selects for those who are likely sicker than those who did not have blood drawn.

Response:

Great point, thank you. We have added this sentence in limitation's section lines 293-294 in the version with tracked changes and lines 264-265 in the new version:

"Lastly, our population only included people who have had a blood test with electrolytes. This fact selects patients who are probably sicker than those who did not have blood tests."

Reviewer \#2

This study by Ferreira et al. investigated the prevalence of dyskalemia in ED of multiple medical centers/hospitals across the France. This was done in a prospective and cross-sectional manner. It is interestingly showed that hypokalemia occurs most often in ED patients while hyperkalemia is rare. Though hypokalemia sounds like "low-risk" but is associated worse outcomes in terms of hospitalization and death. While this is very interesting, there are a couple of issues to be addressed:

1\. First of all, according to Table 1, there is more frequent hospitalization (including in ward and critical care) of patients with hyperkalemia than of patients with hypokalemia or normokalemia. This agrees with more treatments with cardiovascular drugs such as ACEi, CCB, and diuretics, suggesting these patients had CVD more frequently (e.g., hypertension). Please explain this is contradicting with Table 4. In Table 4, the crude OR was 1.51 for the association between hyperkalemia and outcomes but adjusted OR showed an OR\<1.0 (0.61). Why is that and what does this mean?

Response:

This point is well taken. In the Table 4, we adjusted on age, gender, estimated glomerular filtration rate, hemoglobin and Thiazide. Indeed, patients with K\>5 were older, had lower eGFR and lower hemoglobin, all of which are associated with higher risk for death.

When adjusting on those factors, the increase in the risk of event observed with K\>5 is reversed to a rather preventive association (lower than 1). This is because of the major confounding effect of age, eGFR and hemoglobin.

In the revised version of the manuscript we added this sentence to provide this important message to the reader, in the methods section lines 149-151 in the version with tracked changes and lines 129-131 in the new version:

« We adjusted on age, gender, estimated glomerular filtration rate, hemoglobin and Thiazide: patients with K\>5 were indeed older, had lower eGFR and lower hemoglobin (Table 1), all of which being associated with higher risk for death. »

2\. Why in Table 3 and Table 4, K+\>5.0 had different OR and p values for the outcome of hospitalization or death?

Response:

The association of K\>5 with hospitalization/death is changing from one table to the other because of a different reference category. In the Table 4, the reference group (3.5-5) is larger, and at lower risk for event than the reference group (4-5). This directly increases the association of K\>5 with outcome in Table 4 vs Table 3. We have now made this clearer in the manuscript by making clear what is the reference category in the methods section (stating now, line 129 in the version with tracked changes and line 112 in the new version that "normal potassium range was considered when potassium levels were between 4 and 5mmol/L or 3.5 to 5mmol/L depending on the threshold considered") and in the respective tables.

Please see the revised version of the manuscript.

3\. The comparison between your study with the French cohort of 1318 patients should be removed from the abstract and the results part. It is appropriate to keep that in the discussion.

Response:

We proceeded accordingly and removed this part from the abstract, and these points are detailed in the discussion section. Please see the revised version of the manuscript.

4\. What does MRAs stand for in Table 1? Please make sure you have spelled out all abbreviations in the text and notes for tables.

Response:

Thank you. MRAs stands for mineralocorticoid receptor antagonists. We have checked all abbreviations and added them to the respective legends of the tables. Please see the revised version of the manuscript.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: You have adequately addressed my comments. Congratulations! Please make sure that you will make the underlying data for this manuscript fully available to the journal.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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